College of Medicine, Nankai University, Tianjin, China; Department of Urology, Nankai University Affinity The Third Central Hospital, Tianjin, China; Department of Urology, The Third Central Hospital of Tianjin, Tianjin, China; Departments of Urology, Pathology, and The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
College of Medicine, Nankai University, Tianjin, China; Department of Urology, Nankai University Affinity The Third Central Hospital, Tianjin, China; Department of Urology, The Third Central Hospital of Tianjin, Tianjin, China.
J Biol Chem. 2024 May;300(5):107297. doi: 10.1016/j.jbc.2024.107297. Epub 2024 Apr 18.
A growing body of evidence shows that vasculogenic mimicry (VM) is closely related to the invasion and metastasis of many tumor cells. Although the estrogen receptor (ER) can promote initiation and progression of renal cell carcinoma (RCC), how the downstream biomolecules are involved, and the detailed mechanisms of how ER expression is elevated in RCC remain to be further elucidated. Here, we discovered that long noncoding RNA (LncRNA)-SERB is highly expressed in tumor cells of RCC patients. We used multiple RCC cells and an in vivo mouse model for our study, and results indicated that LncRNA-SERB could boost RCC VM formation and cell invasion in vitro and in vivo. Although a previous report showed that ERβ can affect the VM formation in RCC, it is unclear which factor could upregulate ERβ. This is the first study to show LncRNA-SERB can be the upstream regulator of ERβ to control RCC progression. Mechanistically, LncRNA-SERB may increase ERβ via binding to the promoter area, and ERβ functions through transcriptional regulation of zinc finger E-box binding homeobox 1 (ZEB1) to regulate VM formation. These results suggest that LncRNA-SERB promotes RCC cell VM formation and invasion by upregulating the ERβ/ZEB1 axis and that therapeutic targeting of this newly identified pathway may better inhibit RCC progression.
越来越多的证据表明,脉管生成拟态(VM)与许多肿瘤细胞的侵袭和转移密切相关。虽然雌激素受体(ER)可以促进肾细胞癌(RCC)的发生和进展,但下游生物分子如何参与,以及 ER 表达在 RCC 中升高的详细机制仍有待进一步阐明。在这里,我们发现在 RCC 患者的肿瘤细胞中高度表达长非编码 RNA(LncRNA)-SERB。我们使用多种 RCC 细胞和体内小鼠模型进行研究,结果表明 LncRNA-SERB 可以在体外和体内促进 RCC VM 的形成和细胞侵袭。虽然之前的一份报告表明 ERβ 可以影响 RCC 中的 VM 形成,但尚不清楚哪种因子可以上调 ERβ。这是第一项表明 LncRNA-SERB 可以作为 ERβ 的上游调节剂来控制 RCC 进展的研究。从机制上讲,LncRNA-SERB 可能通过与启动子区域结合来增加 ERβ,而 ERβ 通过锌指 E 盒结合同源盒 1(ZEB1)的转录调节来发挥作用,从而调节 VM 的形成。这些结果表明,LncRNA-SERB 通过上调 ERβ/ZEB1 轴促进 RCC 细胞 VM 的形成和侵袭,而针对这一新鉴定途径的治疗性靶向可能更好地抑制 RCC 的进展。